Wegovy slashes risk of serious heart events: What this means for patients and insurers

Emily Field, head of European Pharmaceutical Research at Barclays, joins ‘Squawk Box’ to discuss a new study that suggests that the weight-loss drug Wegovy reduces the risks of heart attacks, what these results mean for patients and insurers, and more.